- Home
- TRVI vs CMP Comparison
TRVI vs CMP Comparison
Compare TRVI & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- CMP
- Stock Information
- Founded
- TRVI 2011
- CMP 1993
- Country
- TRVI United States
- CMP United States
- Employees
- TRVI N/A
- CMP N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- CMP Other Metals and Minerals
- Sector
- TRVI Health Care
- CMP Basic Materials
- Exchange
- TRVI Nasdaq
- CMP Nasdaq
- Market Cap
- TRVI 725.7M
- CMP 781.2M
- IPO Year
- TRVI 2019
- CMP 2003
- Fundamental
- Price
- TRVI $7.01
- CMP $18.81
- Analyst Decision
- TRVI Strong Buy
- CMP Hold
- Analyst Count
- TRVI 10
- CMP 3
- Target Price
- TRVI $19.35
- CMP $20.00
- AVG Volume (30 Days)
- TRVI 2.0M
- CMP 446.4K
- Earning Date
- TRVI 11-05-2025
- CMP 08-11-2025
- Dividend Yield
- TRVI N/A
- CMP N/A
- EPS Growth
- TRVI N/A
- CMP N/A
- EPS
- TRVI N/A
- CMP N/A
- Revenue
- TRVI N/A
- CMP $1,225,200,000.00
- Revenue This Year
- TRVI N/A
- CMP $11.87
- Revenue Next Year
- TRVI N/A
- CMP $3.28
- P/E Ratio
- TRVI N/A
- CMP N/A
- Revenue Growth
- TRVI N/A
- CMP 7.27
- 52 Week Low
- TRVI $2.36
- CMP $7.51
- 52 Week High
- TRVI $8.78
- CMP $22.69
- Technical
- Relative Strength Index (RSI)
- TRVI 44.05
- CMP 40.04
- Support Level
- TRVI $7.09
- CMP $18.34
- Resistance Level
- TRVI $8.78
- CMP $19.53
- Average True Range (ATR)
- TRVI 0.43
- CMP 0.58
- MACD
- TRVI -0.07
- CMP -0.01
- Stochastic Oscillator
- TRVI 4.32
- CMP 26.55
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.